Grace Dy, MD

PrintE-mail
Associate Professor, Department of Medicine
Roswell Park Cancer Institute

Profile

Areas of Expertise: 
Lung cancer
Mesothelioma
Thymic malignancies

Research

Research Interests: 
Phase I clinical trials
Novel targets for lung cancer therapy

Background Information

Education and Training: 
MD - University of Santo Tomas, Manila, Philippines
Residency: 
Mayo Clinic College of Medicine, Rochester, MN
Board Certification: 
Hematology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Fellowships: 
Mayo Clinic College of Medicine, Rochester, MN

Publications

Publications: 
  • Adjei AA, Schild SE, Rowland Jr KM, Stella PJ, Ziegler KLA, Gandara DR, Adjei AA, Molina JR, Dy GK, Mandrekar SJ, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. Journal of clinical oncology 2010; 28(4):614-619
  • Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KLA, Endo C, Molina JR, Schild SE, Adjei AA. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Journal of thoracic oncology 2010; 5(9):1346-1353
  • Dy G. SRC inhibitors. Journal of thoracic oncology 2010; 5(12 Suppl. 6):S466-S467
  • Dy G. MEK/MAPK inhibitors. Journal of thoracic oncology 2010; 5(12 Suppl. 6):S474-S475
  • Dy G. Novel taxanes/epothilones. Journal of thoracic oncology 2010; 5(12 Suppl. 6):S490-S491
  • Dy GK , Schild SE , Mandrekar S , Nair S , Wender DB , Steen PD , Molina JR , Rowland Jr KM , Hillman SL , Adjei AA. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: north Central Cancer Treatment Group Study N0326. Cancer 2010; 116(24):5686-5693
  • Adjei AA, Chai F, Savage R, Means JA, Skupien D, Fetterly GJ, Ma W, Dy GK, Sosman JA, Puzanov I. A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. Journal of clinical oncology 2010; 28(15 Suppl.):3024
  • Chow LQ, Laurie SA, Belani CP, Dy GK, Fortin C, Patricia D, Gupta AK, Kopit J, Zhang S. Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors. Journal of clinical oncology 2010; 28(15 Suppl.):2547
  • Dy GK, Adjei AA, Molina JR, Schild SE, Stella PJ, Lyss AP, Ansari RH, Ross HJ, Nelson GD, Mandrekar SJ, North Central Cancer Treatment Group . A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). Journal of clinical oncology 2010; 28(15 Suppl.):7603
  • Ma W, Adjei AA, Wilhelm F, Bellemarre S, Messersmith WA, Ghalib MH, Dy GK, Freas E, Mani S, Jimeno A. Rational combination of a novel cell cycle inhibitor ON01910.Na with gemcitabine in patients with advanced solid tumors. Journal of clinical oncology 2010; 28(15 Suppl.):e13515
  • Qi Y, Dy GK, Nelson GD, Schild SE, Mandrekar SJ, Adjei AA. Incidence of bleeding and thrombosis among elderly patients (pts) undergoing systemic chemotherapy in advanced non-small cell lung cancer (NSCLC): An analysis of North Central Cancer Treatment Group (NCCTG) trials. Journal of clinical oncology 2010; 28(15 Suppl.):e18093
  • Schild SE, Foster NR, Kugler JW, Northfelt DW, Thomas SP, Sarkaria JN, Rowland KM, Dy GK, Molina JR, Adjei AA. N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). Journal of clinical oncology 2010; 28(15 Suppl.):7085
  • Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, Kalemkerian GP. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES SCLC). Journal of clinical oncology 2010; 28(15 Suppl.):e18041
  • Demmy TL, Tomaszewski G, Dy GK, Yendamuri S, Nwogu C, Pendyala L, Ramnath N, Adjei AA. Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results). Annals of thoracic surgery 2009; 88(2):385-390; discussion 390-391
  • Dy GK, Adjei AA. Emerging therapeutic targets in non-small cell lung cancer. Proceedings of the American Thoracic Society 2009; 6(2):218-223
  • Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clinical colorectal cancer 2009; 8(2):88-93
  • Adjei AA, Huang H, Dy GK, Salavaggione OE, Endo C, Yu C. Functional characteristics of human epidermal growth factor receptor (EGFR) polymorphisms. European journal of cancer (Oxford, England : 1990) 2010; 8(7):175
  • Britten CD, Adjei AA, Millham R, Houk B, Wainberg ZA, Guthrie T, Dy G, LoRusso PM. First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics. European journal of cancer (Oxford, England : 1990) 2010; 8(7):121-122
  • Chow LQ, Salvati M, Chow P, Gupta A, Kopik J, Kurland J, Dy G, Adjei A. Translational approach using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography (FDG-PET) in xenograft models to identify the optimal dosing regimen in a phase I trial of intercalated BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors. Journal of thoracic oncology 2010; 5(12 Suppl. 7):S534-S535
  • Chow LQ, Salvati M, Chow P, Gupta A, Kopik J, Kurland J, Dy G, Adjei A. Using FDG-PET in xenograft models to identify dosing regimen in a phase I trial of intercalated BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors. Journal of thoracic oncology 2010; 5(12 Suppl. 5):S404
  • Dy GK. Dalotuzumab. Humanized anti-CD221 monoclonal antibody oncolytic. Drugs of the future 2010; 35(8):609-612
  • Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, Kalemkerian GP. Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. Journal of thoracic oncology 2011; 6(6):1117-1120
  • Shao H, Tang H, Salavaggione OE, Yu C, Hylander B, Tan W, Repasky E, Adjei AA, Dy GK. Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer. Journal of thoracic oncology 2011; 6(6):998-1005
  • Dy GK, Adjei AA. Systemic cancer therapy: evolution over the last 60 years. Cancer 2008; 113(7 Suppl.):1857-1887
  • Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer research 2008; 68(15):6145-6153
  • Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clinic proceedings 2008; 83(3):355-367
  • Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JR, Ames MM, Adjei AA. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer research 2007; 67(18):8772-8782
  • Lorusso PM, Jin JY, Cheeti S, Chang I, Colburn D, Low JA, Leichman L, Berlin J, Adjei A, Dy G, Jimeno A, Graham RA. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clinical cancer research 2011; 17(17):5774-5782
  • Reinholz MM, Mandrekar SJ, Foster N, Meyers JP, Kitzmann KA, Jett JR, Bernath AM, Wender D, Zinner R, Dy G, Molina JR, Lingle WL, Adjei AA. Circulating tumor cell Cytokeratin-19 gene expression as a prognostic factor in lung cancer: Analysis based on North Central Cancer Treatment Group (NCCTG) clinical trials (N0423/426). Journal of thoracic oncology 2011; 6(6):S1076-S1077
  • Adjei AA, Sosman JA, Martell RE, Dy GK, Goff LW, Ma WW, Horn L, Fetterly GJ, Michael SA, Means JA, Chai F, Lamar M, Strauss GM, Chiang W, Jarboe J, Schwartz BE, Puzanov I. Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3034
  • Besse B, Soria J, Gomez-Roca C, Ware JA, Adjei AA, Dy GK, Shankar G, Brachmann RK, Groen HJ. A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3044
  • Gore L, Lewis K, Von Hoff DD, Weiss GJ, Ramanathan RK, Adjei AA, Dy GK, Ma WW, Clendeninn NJ, Leffingwell DP, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh L, Dubowy RL, Jeffers M, Rajagopalan P, Weekes CD. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3007
  • Ma WW, Messersmith WA, Dy GK, Freas E, Whitworth A, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3101
  • Sosman JA, Adjei AA, LoRusso P, Michael SA, Dy GK, Bowditch A, Chmielowski B, Lee S, Walker RM, Faucette S, Izmailova ES, Bozon V, Ribas A. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):TPS145
  • Adjei A, Infante J, Eckhardt SG, Novello S, Jones S, Dy G, Huff A, Graham A, Burris H, Ottesen L. Phase Ib trial (NCT00619424, VEG109607) of pazopanib (GW786034) and erlotinib administered concurrently. European journal of cancer (Oxford, England : 1990) 2009; 7(2):546
  • Adjei AA, Dy GK, Mandrekar SJ, Endo C, Salavaggione OE, Molina JR, Schild SE, Adjei AA. Pemetrexed pharmacogenomics: haplotype analyses of transport and activation/inactivation gene polymorphisms and the therapeutic outcome in non-small cell lung cancer, an NCCTG N0026 based study. Journal of thoracic oncology 2007; 2(8 Suppl.):S445
  • Adjei AA, Leil TA, Endo C, Dy GK, Salavaggione OE, Reid JR, Mandrekar S, Molina JR, Ames MM, Adjei AA. Functional polymorphisms in the human Folylpolyglutamate Synthase (FPGS) gene may influence efficacy and/or toxicity of Pemetrexed. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:178-179
  • Infante J, Bendell J, Dy GK, Ma WW, Novello S, Huff AC, Graham A, Burris H, Ottesen LH, Adjei AA. Phase Ib study of pemetrexed administered in combination with pazopanib (GW786034). Journal of thoracic oncology 2009; 4(9 Suppl. 1):S413
  • Riely GJ, Gettinger SN, Stoller RG, Gabrail NY, Dy GK, Weiss GJ, Tunkey C, Skliris G, Strychor S, Dunbar J, DeLucia D, Ross RW, Gray JE. Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):7516
  • Molina JR, Dy GK, Foster NR, Allen Ziegler KL, Adjei A, Rowland KM, Aubry M, Flynn PJ, Mandrekar SJ, Schild SE, Adjei AA, North Central Cancer Treatment Group (NCCTG). A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):7513
  • Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. Journal of hepatology 2012; 56(1):176-183
  • Groen H, Adjei AA, Dy GK, Ware JA, Shankar G, Brachmann RK, Besse B, Bahleda RK, Gomez-Roca C, Soria J. A Phase Ib Study to Evaluate the P13-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC). European journal of cancer (Oxford, England : 1990) 2011; 47(Suppl. 1):S595
  • Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. Journal of thoracic oncology 2012; 7(2):419-426
  • LoRusso PM, Jimeno A, Dy G, Berlin J, Leichman L, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA. Evaluation of optimal dosing schedule on steady-state pharmacokinetics of orally administered hedgehog pathway inhibitor GDC-0449 in cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1310
  • Musib L, Eppler S, Choo E, Deng A, Miles D, Hsu B, Rosen L, Sikic B, LoRusso P, Ma W, Goldman J, Fisher G, Weise A, Dy G, Chan I, Ware J. Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 study. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1304
  • Shao H, Tang H, Gao C, Zhang H, Dy G, Yu C, Adjei A, Roberts L. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated antitumor efficacy in primary HCC cancer in vitro and in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #5363
  • Zhang H, Tang H, Shao H, Gao C, Hylander BL, Repasky EA, Dy GK, Ma WW, Yu C, Adjei AA. Mcl-1 downregulation plays a crucial role in the synergistic anticancer activities between PI-3 kinase inhibitors and histone deacetylase inhibitors in primary NSCLC tumors in vitro and in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1
  • Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clinical cancer research 2012; 18(7):2048-2055
  • Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. Journal of thoracic oncology 2012; 7(5):919-922
  • Ramnath N, Daignault-Newton S, Dy GK, Muindi J, Adjei A, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Johnson CS, Trump DL. A phase I/II clinical trial of intravenous (I.V.) calcitriol with fixed doses of cisplatin and docetaxel in advanced non-small cell lung cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18118
  • Fu S, Nemunaitis JJ, Bessudo A, Bauman JE, Hamid O, Witta SE, Dy GK, Lai C, Laliberte R, Voi M. A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e13101
  • Dy GK, Molina JR, Qi Y, Ansari RH, Thomas SP, Ross HJ, Meyers JP, Adjei A, Mandrekar SJ, Adjei AA, North Central Cancer Treatment Group . N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #7555
  • Mandrekar SJ, Foster NR, Qi Y, Dy GK, Jatoi A, Molina JR, Jett JR, Stella PJ, Schild SE, Adjei AA, Alliance (North Central Cancer Treatment Group) . Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #7605
  • Martell RE, Puzanov I, Ma WW, Santoro A, Dy GK, Goff LW, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Simonelli M, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4117
  • Means-Powell JA, Adjei AA, Puzanov I, Dy GK, Goff LW, Ma WW, Fetterly GJ, Michael SA, Chai F, Lamar M, Schwartz BE, Sosman JA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #8519
  • Puzanov I, Sosman JA, Santoro A, Martell RE, Dy GK, Goff LW, Ma WW, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Strauss GM, Zucali PA, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4545
  • Schild SE, Foster NR, Molina JR, Dy GK, Rowland KM, Sarkaria JN, Thomas SP, Northfelt DW, Kugler JW, Adjei AA, North Central Cancer Treatment Group (NCCTG) . N0321: A phase II study of bortezomib, paclitaxel, carboplatin (CBCDA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #7073
  • Farooq A, Dy GK, Demmy TL, Bogner P, Nowadly C, Tan W, Chen H, Yendamuri SS, Nwogu CE, Bushunow PW, Adjei AA, Ramnath N. Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e17535
  • Dy GK. EGFR tyrosine kinase inhibitors in lung cancer: Clinical implications of mutations and treatment resistance. International journal of targeted therapies in cancer 2012; September:50-54